Understanding the Market | RemeGen rose nearly 5% as 10 research projects were showcased at ESMO, institutions optimistic about its accelerated overseas expansion
RemeGen's stock price rose nearly 5%, up 4.81% as of the time of publication, trading at HKD 96.95, with a transaction volume of HKD 706 million. The company presented 10 studies at the 2025 European Society for Medical Oncology (ESMO) annual meeting, with the Phase III study data of Vadastuximab being published for the first time and set to be featured in the New England Journal of Medicine. Huatai Securities believes that the global competitiveness of the company's pipeline will accelerate overseas expansion, maintaining a "Buy" rating
According to Zhitong Finance APP, RemeGen (09995) rose nearly 5%, up 4.81% to HKD 96.95 as of the time of writing, with a transaction volume of HKD 706 million.
In terms of news, from October 17 to 21 local time, the 2025 European Society for Medical Oncology (ESMO) Annual Meeting will be held in Berlin, Germany. At this year's conference, RemeGen will showcase 10 major research studies. Among them, the Phase III study data of RC48-C016 using Vadastuximab for first-line treatment of urothelial carcinoma will be prominently announced for the first time at the conference chair forum and will be published in full online in the New England Journal of Medicine (NEJM). In addition, the Phase III clinical research data of Taitasib for the treatment of IgA nephropathy will be presented in the form of a "Late-Breaking Oral" report at the 2025 American Society of Nephrology (ASN) Annual Meeting, which will be held from November 5 to 9 in Houston, USA.
Huatai Securities believes that the intensive data readouts fully confirm the global competitiveness of the company's pipeline and are expected to accelerate its overseas expansion: 1) The overseas Phase III study of Vadastuximab is steadily advancing, and the firm expects the BLA for the 2LUC indication to be ready by early 2026; 2) RC148 has received CDEBTD, and the overseas Phase I/II clinical trial has been approved by the FDA, showing potential for overseas expansion; 3) The global Phase III enrollment of Taitasib MG is proceeding smoothly, and pSS is expected to become the next key indication. Maintain "Buy"
